Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines

Status and phase: Completed; Phase 3

Conditions: Advanced Prostate Adenocarcinoma

Treatments: Drug: Leuprolide Acetate 3.75 MG/ML

Study type: Interventional

Funder types: Industry

Identifiers

NCT04914195

BSV_LEUPR_18_05

Details and patient eligibility

About

This is a Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 clinical study to compare the efficacy, safety, and pharmacokinetics of leuprolide acetate for injection 3.75mg (depot) of two brands (Luprodex and Lucrin) administered in subjects with advanced adenocarcinoma of the prostate.

Approximately 168 subjects (males )of age above 18 years fulfilling the eligibility criteria will be enrolled. The IP will be given as a monthly dose for two cycles on day 0 and day 28.

The pharmacokinetic analysis will be done for 12 patients receiving Luprodex. The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.

Enrollment: 155 patients

Sex: Male

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male subjects aged above 18 years.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate at stage T1b-4, Nany, Many in subjects, who would benefit from a GnRH agonist.
3. Baseline Testosterone of >1.50 ng/mL or >150 ng/dL.
4. For subjects with radical prostatectomy, an increase of 0.2 ng/mL or 20 ng/dL in PSA from previous test on two consecutive tests. For subjects with prostate irradiation a rise of greater than or equal to 2.0 ng/mL or 200 ng/dL PSA above the nadir.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Appendix 2).
6. Life expectancy of at least 6 months from screening.
7. Adequate organ and immune system function
8. Willing to participate and sign the informed consent as per regulatory requirements.

Exclusion criteria

1. Evidence of brain metastases.

2. Evidence of spinal cord compression.

3. Evidence of urinary tract obstruction, where a flare in disease could put subject at significant risk in the opinion of the Investigator.

4. Received prostate cancer therapies like immunotherapy (antibody therapies, tumor vaccines), external radiotherapy, brachytherapy, chemotherapy or biological response modifiers (e.g. cytokines) within two months of enrollment.

5. Undergone any prostate surgery (e.g. transurethral resection of the prostate (TURP), radical prostatectomy) within two weeks of enrollment.

6. Under the effects of any other hormonal therapy, including anti-androgens for treatment of prostate cancer within three months of baseline.

7. Received leuprolide (leuprorelin) previously.

8. Had an orchiectomy, adrenalectomy or hypophysectomy.

9. Had used any investigational drug, biologic, or device within five half-lives of its physiological action or three months, whichever is longer, before enrollment.

10. Anticipated to need concomitant hormonal, anti-androgen, radiotherapy, chemotherapy, immunotherapy or surgical therapy for prostate cancer throughout the duration of the study.

11. Used over-the-counter (OTC) or alternative medical therapies which has an estrogenic or anti-androgenic effect (e.g., Glycyrrhiza, Dehydroepiandrosterone (DHEA), PC-SPES, saw palmetto) within three months prior to enrollment.

12. Used finasteride, dutasteride, estrogens, megestrol acetate, anti-androgens (Bicalutamide, Flutamide, or Cyproterone), and ketoconazole within three months prior to baseline.

13. Co-existent malignancy or a history of malignancy, with the exception of basal and/or squamous cell carcinomas of the skin.

14. Uncontrolled congestive heart failure within six months before baseline.

15. Experienced a myocardial infarction or a coronary vascular procedure (e.g. balloon angioplasty, coronary artery bypass graft surgery) within six months before baseline.

16. Significant symptomatic cardiovascular disease within six months of baseline.

17. Experienced venous thrombosis within six months of baseline.

18. Uncontrolled hypertension (≥160/100 mmHg) or symptomatic hypotension within three months before baseline.

19. Insulin-dependent diabetes mellitus (Type I diabetes mellitus).

20. History of drug abuse within six months of baseline.

21. Serious intercurrent illnesses or diseases (e.g. hematological, renal, hepatic, respiratory, endocrine, psychiatric) that might interfere with the treatment outlined in the protocol.

22. Receiving anticoagulants or antiplatelet medications and not receiving a stable dose for three months before baseline. Receiving warfarin-derivative anticoagulants with International normalized ratio (INR) outside therapeutic range for the clinical indication for which the anticoagulant has been prescribed.

23. Known hypersensitivity to GnRH, GnRH agonists or any excipients of Leuprolide (leuprorelin).

24. Positive test for HIV, HCV, HbsAg at Screening.

25. History of:

    1. Immunization within four weeks of baseline
    2. Flu shots within two weeks of baseline
    3. Donation or receipt of blood or blood products within two months of baseline
    4. Anaphylaxis
    5. Skin disease which would interfere with injection site evaluation
    6. Dermatographism (Physical urticaria).

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

155 participants in 2 patient groups

Leuprolide acetate 3.75 mg Depot (Luprodex)

Experimental group

Description:

Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29

Treatment:

Drug: Leuprolide Acetate 3.75 MG/ML

Leuprolide acetate 3.75 mg Depot (Lucrin)

Active Comparator group

Description:

Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29

Treatment:

Drug: Leuprolide Acetate 3.75 MG/ML